Valneva SE VALN 深 沪
等待开盘 11-29 09:30:00 美东时间
9.355
-0.185
-1.94%
华盛通- 最 高9.41
- 今 开9.41
- 成交量 2.02万股
- 最 低 9.21
- 昨 收 9.54
- 总市值 8.04亿
- 52周最高 12.25
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 3.62
- 委 比 62.62%
- 总股本 8591.70万
- 历史最高 67.84
- 量 比 0.67
- 振 幅 2.10%
- 历史最低 3.62
- 每 手 1
- 风险率 2.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Valneva Announces Strategic Consolidation of French Operations
Valneva ( ($VALN) ) has shared an update. On November 26, 2025, Valneva SE anno...
11-28 19:57
Valneva Plans To Close Facilities In Nantes, France, To Consolidate Operations At Lyon Site
Valneva SE (NASDAQ:VALN, PARIS:VLA) today announced a strategic initiative to optimize its organizational footprint in France as part of the Company's ongoing efforts
11-27 00:31
快讯 | Valneva SE - 辉瑞计划于2026年向美国食品药品监督管理局（FDA）提交生物制品许可申请，并向欧洲药品管理局（EMA）提交上市授权申请（MAA）。
Valneva SE - Pfizer Aims to Submit a Biologics License Application to U.S. FDA ...
11-26 14:02
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
Antibody levels remained well above baseline across all six serotypes and age g...
11-26 14:00
Valneva Q3 EPS $(0.61) Misses $(0.30) Estimate, Sales $34.386M Miss $50.250M Estimate
Valneva (NASDAQ:VALN) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.30) by 103.33 percent. This is a 306.67 percent decrease over losses of $(0.15) per share from the
11-21 06:26
Valneva SE reports Q3 results
Valneva SE press release (OTCPK:INRLF): 9M Revenue of €127M. Cash and cash equivalents of €143.5 million at end of September 2025 More on Valneva Valneva Outlook: Safety Blow To Ixchiq And Valuation C...
11-20 19:10
First locally-acquired chikungunya case reported in U.S. since 2019
A person in Nassau County, New York, has tested positive for the chikungunya virus, a case state health officials confirmed as the first locally acquired incidence of the mosquito-borne disease in the...
10-16 01:46
Valneva Secures $500 Million Financing to Bolster Vaccine Pipeline
Valneva ( ($VALN) ) has provided an announcement. On October 6, 2025, Valneva S...
10-07 01:17
Valneva Reports Long-lasting Antibody Persistence for Chikungunya Vaccine
The latest announcement is out from Valneva ( ($VALN) ). On September 30, 2025,...
10-07 00:28
Valneva's IXCHIQ Shows 95% Antibody Seroresponse Sustained Four Years After Single Dose In Adults Aged 18 To 65+
Long-lasting antibody persistence was comparable in older (65+) and younger adultsLong-term antibody persistence is a key competitive advantage for a vaccine targeting unpredictable outbreak diseases like chikungunya
09-30 13:25
